Quris AI

Quris-AI is heading to SOT 2025! We’re excited to exhibit at the 64th Annual SOT Meeting & ToxExpo in Orlando, Florida, March 16-20, 2025! Visit us at Booth #1265 to discover how we are revolutionizing drug safety prediction with our AI-powered Bio-AI platform. Let's connect and explore the future of predictive toxicology—reducing drug failure rates and enhancing patient safety through cutting-edge technology. #SOT2025 #ToxExpo #DrugSafety #AIinPharma #Biotech #PharmaInnovation #QurisAI

Revolutionizing Drug Development with Bio-AI ?? At Abu Dhabi Global Healthcare Week, our Founder and CEO, Isaac Bentwich, explored how AI is reshaping drug development—eliminating reliance on animal testing, predicting patient safety with greater accuracy, and accelerating clinical trials. As the industry moves toward a smarter, more ethical future, Bio-AI is leading the way in ensuring safer, faster, and more cost-effective drug discovery. #BioAI #DrugSafety #FutureofMedicine #ADGHW #AIinHealthcare #QurisAI

Quris AI is pioneering AI-driven drug development. Traditional clinical trials are expensive and can be inaccurate, but Quris' Bio-AI Clinical Prediction Platform is changing that. By integrating AI with patient-on-chip technology, Quris is creating safer, more efficient drug testing processes—revolutionizing the pharma industry. See how this innovation is reshaping medicine: https://bit.ly/3MaBoCa #PharmaInnovation #ArtificialIntelligence #InsideTheBlueprint #DrugDevelopment #BioTech

Predicting Patient Safety with Precision ?? Traditional drug testing models are riddled with uncertainty, leading to costly failures and patient risks. By integrating AI-driven insights with organ-on-a-chip technology, drug safety can now be predicted with unmatched accuracy—before clinical trials even begin. With Merck KGaA among those adopting this cutting-edge approach, the industry is moving toward a future where safer, more effective drugs reach patients faster. The shift is happening now. Read more: https://lnkd.in/dtAaByc8 #BioAI #DrugSafety #NoMoreGuesswork #FutureofMedicine #ClinicalTrials

Big news! Merck KGaA, Darmstadt, Germany, has adopted Quris AI's Bio-AI platform for preclinical small molecule safety testing after a successful collaborative two-year validation study. Together, we are accelerating safer drug development and reducing reliance on animal testing. #AI #PharmaInnovation #DrugSafety #QurisAI

Quris AI's latest article, created in collaboration with MBZUAI (Mohamed bin Zayed University of Artificial Intelligence), has been published at NeurIPS 2024 and is featured at the NIPS conference in Canada! This groundbreaking work showcases how AI and organ-on-a-chip technologies are advancing predictive drug safety and transforming healthcare. We’re proud to be part of this innovation and look forward to more collaborations in the future! ?? Check out the article here: https://lnkd.in/dXZpsqdz #NeurIPS2024 #AI #DrugSafety #Innovation #Collaboration

?? Exciting News from Quris-AI! ?? We are honored to announce that Quris-AI has been awarded the prestigious Frost & Sullivan Best Practices Recognition! This recognition reinforces the value of our mission to bring safer, more effective medicines to patients faster, while redefining the future of drug development. Stay tuned as we continue to push boundaries, innovate, and transform the way the pharma industry approaches drug discovery. Read more at: https://lnkd.in/dUYJiNr8 #QurisAI #FrostAndSullivan #Innovation #DrugSafety #Biotechnology #AI

?? Quris-AI recognized as one of the world’s top 8 longevity healthcare technology companies! We’re honored to share that the prestigious The Healthcare Technology Report 2024, published yesterday, recognized Quris-AI as one of only eight Longevity healthcare technology companies in its Top 100 Healthcare Technology Companies list.? “Quris is revolutionizing the drug development process; the company is pioneering clinical trials on chips, testing thousands of novel drug candidates on hundreds of miniaturized “patients-on-a-chip.” Read more here: https://lnkd.in/gdphXRAS

At Quris-AI, we constantly pursue innovative methods to generate proprietary data, enhancing the precision of our ML-driven DILI (Drug-Induced Liver Injury) predictions. Our latest publication, highlighted as a cover article in ACSOmega, presents a groundbreaking approach to monitoring glucose metabolism within liver spheroids, a marker of metabolic safety and potential drug toxicity. Our team has developed several novel glucose sensors (NCEs) designed for both intra- and extracellular monitoring under physiologically relevant conditions. These sensors demonstrate exceptional sensitivity and selectivity, providing deeper insights into liver cell metabolic homeostasis. This advancement not only reinforces our commitment to leveraging cutting-edge technologies but also underscores our mission to push the boundaries of drug safety prediction. Explore the complete findings in the full paper led by our VP of Chemical Sensing, Dr. Tamar Getter, PhD, and learn how we’re using innovation to drive the future of safer drug development. #DILIPrediction #DrugSafety #MachineLearning #ArtificialIntelligence #Pharma #LiverModels #DrugDevelopment https://lnkd.in/dZnjpbkh

We’re excited to announce the launch of #FeatureFriday — a weekly series where we spotlight one of the incredible individuals that are part of The Alliance for Artificial Intelligence in Healthcare (AAIH)! This week, we are proud to feature Dr. Isaac Bentwich, Founder and CEO of Quris AI, an artificial intelligence innovator that is disrupting the drug development process, allowing pharma companies to develop safer drugs, faster. Bentwich is a physician and entrepreneur, who has previously founded and led two bio-AI technology companies that led revolutions in medicine and genomics. Bentwich’s passion is leading inter-disciplinary teams of scientists and technologists to tackle impactful challenges in the intersection between machine-learning and life-sciences, and to leverage and commercialize these solutions. One of the companies that Bentwich founded was Rosetta Genomics (NASDAQ:ROSG), which under his leadership analyzed the human genome, discovering hundreds of novel genes, more so than all the universities in the world combined, and delivered novel cancer diagnostics based on these genes. Its subsidiary, Rosetta Green (TASE:RSTG), was acquired by Monsanto for $35M. We are pleased to have Dr. Isaac Bentwich and Quris AI as valued members of the AAIH!